Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
interleukin-4 PE38KDEL cytotoxin · 2 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| interleukin-4 PE38KDEL cytotoxin | BIOLOGICAL | - |
| conventional surgery | PROCEDURE | - |
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or progressive glioblastoma multiforme Previously treated with cytoreductive surgery Unilateral, unifocal tumor with a volume of 5-80 mL Not eligible for further radiotherapy due to prior external beam radiotherapy No multifocal, brain stem...
Interleukin-4 PE38KDEL cytotoxin is an investigational drug being studied for the treatment of brain and central nervous system tumors, including recurrent glioblastoma multiforme, and breast cancer. It is a monoclonal antibody-based therapy developed by Neurocrine Biosciences, Inc. (NBIX). The drug is currently in Phase 2 clinical development.
Interleukin-4 PE38KDEL cytotoxin targets the interleukin-4 receptor, which is expressed on certain tumor cells. The drug is designed to deliver a cytotoxic payload to cells bearing this receptor, potentially leading to their destruction. This mechanism is being evaluated in clinical trials for brain tumors and breast cancer.
Interleukin-4 PE38KDEL cytotoxin is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol NBIX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with brain and central nervous system tumors and breast cancer.
Interleukin-4 PE38KDEL cytotoxin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and a Phase 1 trial has also been completed, both in the United States.
Interleukin-4 PE38KDEL cytotoxin has been studied in two completed clinical trials. NCT00014677 was a Phase 2 trial of NBI-3001 followed by surgery in patients with recurrent glioblastoma multiforme. NCT00039052 was a Phase 1 trial of intravenous interleukin-4 PE38KDEL cytotoxin in patients with recurrent or metastatic kidney cancer, non-small cell lung cancer, or breast cancer.
Yes, interleukin-4 PE38KDEL cytotoxin is also known as NBI-3001. In clinical trial NCT00014677, the drug is referred to as NBI-3001, which is being studied in patients with recurrent glioblastoma multiforme. This alternative name is used in the context of the Phase 2 trial.